XNASACXP
Market cap13mUSD
Dec 31, Last price
0.81USD
1D
-4.57%
1Q
-62.14%
IPO
-86.96%
Name
Acurx Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-15m
L+20.56%
CFO
-10m
L+29.95%
Earnings
Mar 17, 2025
Profile
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 14,578 | 12,093 | |||
Unusual Expense (Income) | |||||
NOPBT | (14,578) | (12,093) | |||
NOPBT Margin | |||||
Operating Taxes | (1) | ||||
Tax Rate | |||||
NOPAT | (14,578) | (12,092) | |||
Net income | (14,578) 20.56% | (12,092) -4.65% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 5,944 | 3,695 | |||
BB yield | -12.25% | -8.58% | |||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | 2,062 | ||||
Net debt | (7,474) | (9,112) | |||
| Cash flow | |||||
Cash from operating activities | (9,801) | (7,542) | |||
CAPEX | 5 | ||||
Cash from investing activities | |||||
Cash from financing activities | 8,163 | 3,695 | |||
FCF | (14,578) | (12,092) | |||
| Balance | |||||
Cash | 7,474 | 9,112 | |||
Long term investments | |||||
Excess cash | 7,474 | 9,112 | |||
Stockholders' equity | (53,204) | (77,271) | |||
Invested Capital | 57,871 | 84,586 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 12,672 | 10,816 | |||
Price | 3.83 -3.77% | 3.98 -7.90% | |||
Market cap | 48,532 12.74% | 43,049 -2.49% | |||
EV | 41,058 | 33,938 | |||
EBITDA | (14,578) | (12,093) | |||
EV/EBITDA | |||||
Interest | 1 | ||||
Interest/NOPBT | |||||